PowerPoint Presentation · This presentation (the “Presentation”) of Valens GroWorks Corp. (the “Company” or “The Valens Company” or “Valens”) is an overview only

TSX: VLNSOTCQX:VLNCF

JUNE 2020

THEVALENSCOMPANY.COM

A W A R D E D T O P E X T R A C T I O N C O M P A N Y 2T S X : V L N S | O T C Q X : V L N C F

NOTICE TO RECIPIENT

This presentation (the “Presentation”) of Valens GroWorks Corp. (the “Company” or “The Valens Company” or “Valens”) is an overview only and does not contain all the information that a prospective investor may require to make investment decisions. This Presentation is for information purposes only and does not constitute an offer to sell or a solicitation to buy any securities of the Company. In making an investment decision, investors must rely on their own examination of the Company, including the merits and risks involved.

FORWARD LOOKING STATEMENTS

This Presentation contains forward-looking statements and forward-looking information. Often, but not always, forward-looking statements can be identified by the use of words or phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and information.

Examples of such statements include: (A) the financial forecast of the Company; (B) the intention to grow the business and operations of the Company; (C) anticipated timing for the availability of the Company’s products to market and expected sale prices; (D)expected growth in the number of users of medical and recreational marijuana anticipated; and (E)the expansion of the Company’s business into other revenue streams.

Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this Presentation. Such forward-looking statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to: expectations regarding the ability of the Company to raise capital and grow through acquisitions; growth strategy, joint venture, other commercial opportunities and the ability of the Company to carry out its stated work program; and expected sources and uses of capital.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements and information contained in this Presentation are expressly qualified in their entirety by this cautionary statement.

The forward-looking statements and information included in this Presentation are made as of the date of this Presentation and the Company assumes no obligation to update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION

To the extent any forward-looking statement in this Presentation constitutes “future-oriented financial information” or “financial outlooks” within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking statements generally, are, without limitation, based on the assumptions and subject to r isks as set out above under the heading “Forward-Looking Statements”. The Company’s actual financial position and results of operations may differ materially from management’s current expectations and, as a result, the Company’s revenue and expenses may differ materially from the revenue and expenses profiles provided in this presentation. Such information is presented for illustrative purposes only and may not be an indication of the Company’s actual financial position or results of operations.

THIRD PARTY INFORMATION

This Presentation includes market and industry data which was obtained from various publicly available sources and other sources believed by the Company to be true. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this presentation, or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Company does not make any representation as to the accuracy of such information.

USE OF NON-GAAP MEASURES

Adjusted EBITDA is a non-GAAP measure used by management that does not have any standardized meaning prescribed by I FRS and may not be comparable to similar measures presented by other companies. Management defines adjusted EBITDA as loss and comprehensive loss from operations, as reported, before interest, tax, depreciation and amortization, and adjusted for removing share-based payments, unrealized gains and losses from short term investments and other one-time and non-cash items including impairment losses. Management believes adjusted EBITDA is a useful financial metric to assess its operating performance on an adjusted basis as described above. A description of these financial measures, including a reconciliation of such measures, to the extent possible, against the most directly comparable I FRS measure, can be found at page 9 of the management’s discussion and analysis of the Company for the three and nine month period ended August 31, 2019.


OUR MISSIONOur mission is to become the world’s most trusted partner for best-in-class cannabis extraction, testing, formulation, product development and custom manufacturing.

RECENT ANNOUNCEMENTS• Entered into distribution agreement

with Cannvalate, Australia’s largest distributor of medical cannabis.

• Three new independent directors to stand for nomination to Board at Annual General Meeting on June 12, 2020.

4T S X : V L N S | O T C Q X : V L N C F

THE VALENS COMPANY IS ACCELERATING INTO CANNABIS 2.0

BEST POSIT IONED TODAY,ACCELERATING INTO TOMORROW EXTRACTION AND NEXT GENERATION PRODUCT CAPABILITIES DRIVE OUR ADVANTAGE


BROADENING END-PRODUCT & DELIVERY CAPABILITIESBroadening our custom offerings to become the largest third-party cannabis product development and manufacturing company in the world

OPERATING WITH GLOBAL STANDARDSReadying our business model for exportation to high value international markets

PROVIDING UNIQUE, CUSTOMIZED OFFERINGSFurther developing our unique, IP based product technology platform offering customized manufacturing services

INCREASING CAPACITYSignificantly increasing existing extraction capacity of hemp and cannabis to keep up with expected demand

BUILDING REPUTATIONGaining more partnerships and establishing ourselves as the trusted partner of choice by various leading international brands and Consumer Packaged Goods (CPG) companies

$0.63b

$2.13b

$0.00b

$0.50b

$1.00b

$1.50b

$2.00b

$2.50b

GROWING CANADIAN RETAIL MARKETINCREASED OPPORTUNITY FOR 2.0 FOCUSED COMPANIES LIKE THE VALENS COMPANY

$2.1b

750+

9

Annualized Retail Sales (C$,b)

AnnualizedRevenue

RetailStores

Product Segments


Source: Statistics Canada

OUR BELIEFTHE MARKET WILL BE DOMINATED BY OIL BASED PRODUCTS

Source: Cowen Equity Research Report (US

Market Share)*Valens forward-looking prediction in the short-term based on market

research

2018

53% 47%

FUTURE*

25%

75%

2016

29%

71%

OIL BASED PRODUCTS

FLOWER BASED PRODUCTS

VAPE PENS

PRE-ROLLS

FLOWER

EDIBLES

CONCENTRATES

OTHER

20%

11%

10%


OUR FOCUSPROVIDE QUALITY PRODUCTS THAT OFFER CUSTOMIZED USER EXPERIENCES TO HELP OUR CUSTOMERS BUILD DIFFERENTIATED, HIGH VALUE BRANDS

CULTIVATION EXTRACTION

PURIFICATION

FORMULATION

PRODUCT MANUFACTURING

BRANDING RETAIL& SALES

VALENS IN THE VALUE CHAINUNLOCKING HIGHER MARGINS FOR OUR CUSTOMERS


VALENS’ OPERATIONS

DRIED CANNABIS OR HEMP

OIL EXTRACTION

CRUDE OILOIL

WINTERIZATION

OIL REFINEMENT(DISTILLATE)

CHROMATOGRAPHY/ SEPARATION

(ISOLATE)

EXTRACTIONCONCEPT IS SIMPLE, QUALITY EXECUTION IS COMPLEX


EXPERTISE THAT DIFFERENTIATESDIVERSITY CREATES COMPETITIVE ADVANTAGE

Capsules, Tinctures, Vapes, Topicals,

Beverages, Edibles and Others

Capsules, Tinctures, Vapes, Topicals,

Beverages, Edibles and Full Spectrum

Concentrates, Vapes, Shatter/Wax,

Crumble/Live Resin, Full Spectrum

Rosin, Hash, Full Spectrum

Add back for experience, flavour

and smell

SUPER/SUB CRITICAL CO2

ETHANOL HYDROCARBONSOLVENT-LESS TERPENE

L E S S C O M M O D I T I Z A T I O N

O N E S I Z E D O E S N O T F I T A L L : H I G H Q U A L I T Y P R O D U C T S N E E D C U S T O M I Z E D P R O C E S S E S


PHASE 1 $

PHASE 2$$

PHASE 3 $$$

BUSINESS STRATEGYDELIVERING SUSTAINABLY STRONG EBITDA MARGINS THROUGH THE CYCLE


EXTRACTION

Utilize technical expertise to develop unique product portfolio and maximize margins

CUSTOM MANUFACTURING

GLOBAL CUSTOM MANUFACTURING

Generate global revenue and high margins in large markets by leveraging experience and best practices

High margin and low risk entry into market through accelerated scale-up

+3 O T H E R S

H I G H Q U A LI T YE X T R A C T I O N

N E X T G E N E R A T I O NP R O D U C T D E V E LO P M E N T

EXTRACTION EXPERTISE FACIL ITATES ROLL-OUT OF CUSTOM MANUFACTURING


TESTINGWE ARE SETTING THE STANDARD


FIRST ISO 17025 ACCREDITED LAB• Consistent use of validated methodologies

CAN PERFORM ANALYSES IN AS LITTLE AS 24 HOURS• Positioning Valens as the go-to lab with turn arounds 4-5x faster than other leading labs

PUBLISHING FULLY VALIDATED, STANDARDIZED,AND TURNKEY SOLUTIONS FOR THE GLOBAL CANNABIS INDUSTRY• Global recognition for methodologies and putting Valens’ name at the forefront of analysis

ADDITIONAL REVENUE SOURCE THROUGH THIRD-PARTY LAB TESTING• Consistent high margin revenue source, mandated by Health Canada

NAMED A “CENTER OF EXCELLENCE IN PLANT BASED SCIENCE” B Y

Market Cap: 135B*

*As at May 29, 2020

FORMULATIONSCUSTOMIZED USER EXPERIENCES NEED CUSTOMIZED PRODUCT FORMULATIONS


P I N E A P P L E E X P R E S S *

Linalool7%

Beta Pinene

5%

Alpha Pinene

3%

Myrcene23%

Limonene18%

Humulene15%

S O R S E E M U L S I O N

C O N C E N T R AT E S F O R M U L AT I O N S

*Example of theterpene make-up of

the cannabis strain,Pineapple Express

Beta Caryophyllene

30%

T E S T I N GM E T H O D O L O G I E S

E X T R A C T I O NM E T H O D O L O G I E S

C A N N A B I N O I D A N D T E R P E N E I S O L A T I O N

VALENS IS BUILDING A DIVERSE IP PORTFOLIO THAT SPANS ACROSS ALLT Y P E S OF PRODUCTS AND SERVICES

100+ TERPENE FORMULATIONS

FORMULATIONSSORSE EMULSION TECHNOLOGY


CURRENT PROBLEMS

VALENS’ SOLUTIONS

The global market for cannabis-based drinks is expected to be worth US$1.4 billion by 2024

- Prohibition Partners

• Shelf stable for over 2 years• Zero cannabis taste, colour or odour• Provides effective consistent dosing• Lower dosage proven sufficient due to increase in

bioavailability when consumed• Resistant to temperature change including boiling,

freezing and thawing• Faster onset making it the safer and more trusted option,

observed in 5-15 minutes versus normal 30 minutes - 2 hours

• Faster offset making it feel exactly like an alcoholic beverage, observed in 45 minutes-2 hours versus normal 4 -8 hours

• Proprietary licensed formula• Exclusive rights in Canada, Mexico, EU, UK and Australia• Access to non-exclusive rights globally

WATER SOLUBILITY

ONSET

OFFSET

SMELL/TASTE

CONSISTENCY

SHELF STABILITY

3 RD PARTY PRODUCT DEVELOPMENT AND CUSTOM MANUFACTURING THE FUTURE OF CANNABIS CONSUMPTION

Tinctures Two-piece caps

Soft gels Oral spray

VALENS 1.0CURRENTLY MANUFACTURING

VALENS 2.0PHASE I

CURRENTLY MANUFACTURINGPHASE IIH2 2020

Beverages

Concentrates

Vape Pens

Edibles

Topicals

More innovative products


FACIL ITY EXPANSION FOR CUSTOM MANUFACTURINGIP BASED PRODUCTS TO STRENGTHEN COMPETITIVE ADVANTAGE AND MARGINS

Crude, Distillate, Full Spectrum, Isolate, Formulation and

Emulsion

Extraction Focused

Crude, Distillate, Full Spectrum, Isolate,

Formulation and Emulsion

Extraction Focused

Capsules, Tinctures, Vapes, Sprays, Edibles, Beverages and

Topicals

Custom Manufacturing Focused

Formulation, Emulsion,

Beverage/Edible Co-packing

Custom Manufacturing Focused

Most output leaving as bulk

oilMost output leaving as a consumer packaged good

TODAY 2020

230 Carion (K1)230 Carion (K1)+ 180 Carion (K2) GTA Facility

+


ACTION PLAN12 MONTH PLAN

DELIVER ON EXISTING CONTRACTSOptimize existing capacity to maximize margin

LAUNCH NEXT GENERATION

PRODUCTSBuild IP portfolio with

differentiated product offering

1 2

3

KELOWNA + GTA EXPANSIONSpeed to market to maintain advantage

GLOBAL EXPANSIONTarget markets and

opportunities that maximize ROI, and export globally with EU

GMP certification

4


INTERNATIONAL EXPANSIONADVANCED DISCUSSIONS IN KEY MARKETS GLOBALLY

GLOBAL MEDICAL MARKET ALONE ESTIMATED AT $180B ANNUALLY IN 10-20 YEARS*

C U R R E N T A R E A SO F I N T E R E S T

C U R R E N T F A C I L I T I E S

P E N D I N G F A C I L I T I E S

A U S T R A L I A

U N I T E D S T A T E S

E U

B R A Z I L

C O L U M B I A

P E R U

U R U G U A Y

ME X I C O

C B D


L O N G T E R M A R E A S O F I N T E R E S T

*Source: Eight Capital Research

BOLTON, ON

KELOWNA, BC

K1 K2

F INANCIALS & OUTLOOKFIRMLY INTO OUR GROWTH PHASE; FOCUSED ON UNLOCKING SHAREHOLDER VALUE

$1.20

$1.02

$0.61

$1.25

$1.44

0

5

10

15

20

25

30

Q1'19 Q2'19 Q3'19 Q4'19 Q1'20

PRICE ($ per gram)

PRODUCTION (MM of grams)

$2.2

$8.8

$16.5

$30.6$32.0

-$2.0

$2.0

$9.8

$17.7$14.3

-5

0

5

10

15

20

25

30

35

REVENUE (MM) EBITDA (MM)

Source: Company Filings, S&P Capital IQNote: Shares outstanding and cash balance based on most recent quarterly financials; presented as Treasury Stock Method. Pharma CMO cohort includes: Catalent Inc., Perrigo Company PLC, Recipharm AB. Packaged Foods CMOcohort includes: Tate & Lyle PLC, J&J Snack Foods Corp., TreeHouse Foods Inc., Hilton Food Group PLC. CanadianCannabis Peers refer to cohort on next slide.


CAPITALIZATION TABLE(In CAD$MM, Unless otherwise noted)Share Price: As of May 29, 2020 $2.65Basic Shares O/S 127.7

Full Diluted Shares O/S 131.7Equity Value 349.0Cash and Cash Equivalents 44.3ITM Securities 6.0Debt 0.0Enterprise Value 298.7

Average Analyst Estimates 2019 2020 2021 2022Revenue 58.1 149.9 220.7 318.7Adjusted EBITDA 27.4 56.7 82.2 95.1EPS -$0.06 $0.24 $0.37 $0.42

Implied Multiples 2019 2020 2021 2022Valens EV/EBITDA 10.9x 5.3x 3.6x 3.1xPharma CMO Average EV/EBITDA* 18.3x 14.7x 13.0x 12.2xPackaged Foods CMO Average EV/EBITDA* 12.5x 14.4x 11.9x 9.3xCanadian Cannabis Peer Average EV/EBITDA* nmf 21.3x 16.7x 10.3x

Valens P/E nmf 11.3x 7.2x 6.3xPharma CMO Average P/E* 26.2x 27.6x 20.2x 17.7xPackaged Foods CMO Average P/E* 23.0x 63.8x 22.8x 17.0xCanadian Cannabis Peer Average P/E* nmf 20.4x 32.0x 36.7x

Analyst Target PriceAverage (7 Analysts) $7.46Implied Return Potential 182%

LARGE DISCOUNT TO PEERS DESPITE STRONG EXECUTION

5x

19x

0x

10x

20x

30x

40x

50x

Jan-19 Feb-19 Mar-19 Apr-19 May-19 Jun-19 Jul-19 Aug-19 Sep-19 Oct-19 Nov-19 Dec-19 Jan-20 Feb-20 Mar-20 Apr-20 May-20

CY

2020

EV

/EB

ITD

A

VLNS CANADIAN CANNABIS PEER AVERAGE

4x

14x

0x

5x

10x

15x

20x

25x

30x

35x

Jan-19 Feb-19 Mar-19 Apr-19 May-19 Jun-19 Jul-19 Aug-19 Sep-19 Oct-19 Nov-19 Dec-19 Jan-20 Feb-20 Mar-20 Apr-20 May-20

CY

2021

EV

/EB

ITD

A

VALENS CANADIAN CANNABIS PEER AVERAGE


No. Of Announced Toll Processing Agreements

11 4 7 2

No. Of Manufacturing Agreements 14 3 11 0

Current Annual Canadian Extraction Capacity

425,000 KG 200,000 KG 300,000 KG 56,000 KG

Types of Extraction 5 2 1 1

ISO 17025 Accredited Testing Lab* Y N N N

EU GMP Certification Pending N Pending Pending

Organic Certification Y N Y N

Cash Flow From Operations ($CAD)Per Latest Filed Quarter

-0.4 M -10.0 M 1.1 M -4.0 M

Net Income, Excluding Exceptions ($CAD)Per Latest Filed Quarter

2.7 M -14.7 M -3.2 M -5.4 M

Enterprise Value ($CAD)Per Comp Table Pg. 23

301 M 385 M 213 M 61 M

EV / EBITDA ($CAD)Per Latest Filed Quarter

5.3x n/a 12.4x n/a

*Sourced from Capital IQ, company presentations, latest filed quarters and news releases

COMPETIT IVE LANDSCAPE


INVESTMENT HIGHLIGHTS

LARGEST EXTRACTION COMPANY IN CANADA.At 425,000 KG of capacity, Valens is equipped to service Canadian demand as well as the global markets with efficiency at scale.

HIGH MARGINS.Operating in one of the highest margin sub-sectors of the cannabis industry with low variability in costs.

PROPRIETARY TECHNOLOGY AND PROCESSES.Decades of experience have resulted in best-in-class proprietary extraction processes that are optimized to produce consistently high-quality products.

FIRST MOVER ADVANTAGE.Founded in 2012, Valens was granted the first Dealer’s License to process cannabis. Our R&D and testing process allows us to quickly identify market trends and adapt to a changing landscape.

MOST DIVERSE EXTRACTION CAPABILITIES.Providing customers with the widest variety of extraction techniques which allows them to produce the largest range of end products.

REVENUE VISIBILITY.Agreements with Consumer Packaged Goods (CPG) companies, brands and Licensed Producers (LPs) provide increased visibility in revenue stream in future quarters.

CUSTOMIZED PRODUCT DEVELOPMENT.Valens formulation and testing expertise allows for the production of a wide array of tinctures, capsules, concentrates, vapes, topicals, beverages and edibles.

IN-HOUSE TESTING LABORATORY.Setting global standards, Valens Labs was the first ISO 17025 accredited lab for cannabis analyses and is endorsed by $100B+ Thermo Fisher Scientific as the Centre of Excellence in Plant Based Science.


APPENDIX : COMP TABLE

Source: Company Filings, S&P Capital IQ As of April 30, 2020; shares outstanding based on most recent quarterly financials and adjusted for share issuancetransactions and other significant publicly disclosed transactions.


Share Equity Enterprise EBITDA EPS EV/EBITDA P/EPrice Value Value 2020 2021 2022 2020 2021 2022 2020 2021 2022 2020 2021 2022(C$mm) (C$mm) (C$mm) (C$mm) (C$mm) (C$mm) (C$mm) (C$mm) (C$mm) (x) (x) (x) (x) (x) (x)

Large Cap LPsCanopy Growth Corporation C$24.21 $8,493 $7,273 -$287 -$63 $211 -$1.83 -$0.58 -$0.19 nmf nmf 34.5x nmf nmf nmfAurora Cannabis Inc. C$19.27 $2,128 $2,458 -$74 $22 $123 -$2.74 -$1.21 -$0.25 nmf 109.9x 20.0x nmf nmf nmfTilray, Inc. US$9.85 $1,724 $2,159 -$70 $7 $103 -$3.10 -$1.36 n.a. nmf nmf 21.0x nmf nmf nmfAphria Inc. C$5.81 $1,663 $1,660 $47 $95 $131 -$0.09 -$0.01 $0.05 35.7x 17.6x 12.7x nmf nmf 114.4xCronos Group Inc. C$9.03 $3,209 $1,330 -$166 -$96 -$3 $0.00 -$0.19 $0.04 nmf nmf nmf nmf nmf 207.6xOrganiGram Holdings Inc. C$2.42 $425 $471 $9 $45 $51 -$0.09 $0.11 $0.23 51.3x 10.4x 9.2x nmf 21.5x 10.5xHEXO Corp. C$0.85 $347 $369 -$22 $10 $20 -$0.12 -$0.02 n.a. Nmf 36.2x 18.6x nmf nmf nmfAverage 43.5x 43.5x 19.3x nmf 21.5x 110.8x

Mid Cap LPsVillage Farms International, Inc. C$7.29 $418 $456 $16 $51 $82 $0.29 $0.99 $1.17 28.7x 8.9x 5.5x 25.1x 7.4x 6.2xSundial Growers Inc. US$0.85 $130 $296 -$25 $0 n.a. -$0.94 -$0.49 n.a. nmf nmf nmf nmf nmf nmfThe Supreme Cannabis Company, Inc. C$0.35 $124 $247 -$20 $12 n.a. -$0.24 -$0.04 n.a. nmf 19.9x nmf nmf nmf nmfZenabis Global Inc. C$0.15 $56 $189 $0 $68 n.a. n.a. n.a. n.a. nmf 2.8x nmf nmf nmf nmfThe Flowr Corporation C$0.59 $74 $188 -$8 $17 $47 -$0.13 $0.01 $0.09 nmf 11.0x 4.0x nmf 118.0x 6.6xWeedMD Inc. C$0.51 $107 $138 $25 $51 n.a. n.a. $0.11 n.a. 5.6x 2.7x nmf nmf 4.6x nmfThe Green Organic Dutchman Holdings Ltd. C$0.44 $148 $171 -$28 -$4 $28 -$0.30 -$0.06 $0.01 nmf nmf 6.1x nmf nmf 43.5xAverage 17.1x 9.0x 5.2x 25.1x 43.3x 18.8x

Small Cap LPsEmerald Health Therapeutics, Inc. C$0.28 $45 $70 n.a. n.a. n.a. n.a. n.a. n.a. nmf nmf nmf nmf nmf nmfDelta 9 Cannabis Inc. C$0.50 $45 $70 $7 $9 $11 $0.02 $0.01 $0.03 10.1x 7.6x 6.2x 25.0x 50.0x 16.7xVIVO Cannabis Inc. C$0.25 $74 $71 -$7 $15 $40 -$0.09 n.a. $0.06 nmf 4.7x 1.8x nmf nmf 4.2xDecibel Cannabis Company Inc. C$0.11 $37 $65 $0 $18 $22 -$0.02 $0.01 $0.03 nmf 3.7x 3.0x nmf 10.5x 3.5xHarvest One Cannabis Inc. C$0.12 $26 $32 -$12 n.a. n.a. -$0.06 n.a. n.a. nmf nmf nmf nmf nmf nmfAverage 10.1x 5.3x 3.7x 25.0x 30.3x 8.1x

Extraction CompaniesThe Valens Company C$2.65 $343 $301 $57 $82 $95 $0.24 $0.37 $0.42 5.3x 3.6x 3.1x 11.3x 7.2x 6.3xMediPharm Labs Corp. C$1.80 $243 $213 $17 $53 $73 -$0.06 $0.13 $0.23 12.4x 4.0x 2.9x nmf 13.6x 8.0xNeptune Wellness Solutions Inc. C$4.12 $400 $385 $1 $47 $62 -$0.40 $0.08 $0.31 nmf 8.2x 6.2x nmf 54.9x 13.4xRadient Technologies Inc. C$0.17 $51 $61 n.a. n.a. n.a. n.a. n.a. n.a. nmf nmf nmf nmf nmf nmfAverage 8.8x 5.3x 4.1x 11.3x 25.2x 9.2x

Average All 21.3x 16.7x 10.3x 20.4x 32.0x 36.7xMedian All 12.4x 8.2x 6.2x 25.0x 13.6x 9.2x

Tyler Robson, B.A. & Sc.Director, Chief Executive Officer & Co-founderBased on Mr. Robson’s impressive contributions to The Valens Company, formerly Valens GroWorks, he was appointed CEO in May 2017 after previously serving as COO. Over the last decade Tyler has worked extensively in cannabis science focusing on research and development, proprietary extraction processing and medical application. Mr. Robson is seen as a thought-leader throughout the industry and his expertise has shown through his impressive client base at Valens where the Company has secured agreements with some of the world’s most renowned cannabis companies.

Chris Buysen, MPAcc, CPA, CAChief Financial OfficerMr. Buysen has over 15 years of diverse financial experience working as a senior financial executive with many public and private organizations in a wide range of industries. During this time, he was responsible for internal and external financial reporting, strategic planning, treasury, tax, information technology, human resources, financial controls and corporategovernance.

Chantel PopoffChief Operating OfficerMr. Popoff has over a decade of experience in managing 21+ Western Canadian retail pharmacy chains, including Shoppers Drug Mart. After her time in pharma, she spent over 6 years in senior managerial roles in the Canadian natural health foodindustry.

Jeff Fallows LLB/MBA, CFA PresidentMr. Fallows is an accomplished finance professional with over 18 years experience working on a wide range of financial transactions in the cannabis, consumer products and industrial products industries. He spent the last 10 years working with a number of cannabis companies to raise capital and has advised on some of the largest transactions in the sector. Prior to joining The Valens Company, Mr. Fallows worked as a Managing Director at AltaCorp Capital Inc.

Everett Knight, CFAEVP, Corporate Development and Capital MarketsMr. Knight holds almost a decade of experience in Portfolio Management and Investments. At Matco Financial, he launched the first ever institutional long only cannabis fund in Canada and managed a small cap fund, ranked #1 in its category. He is known for his thought leadership and his expertise in analyzing, lobbying, investing, advising, & consulting throughout the cannabis value chain.

Paul KunynetzGeneral CounselPrior to joining The Valens Company, Mr. Kunynetz practiced law at McCarthy Tétrault in Toronto where he gained extensive experience working on high-profile and complex transactions. His practice focused on mergers and acquisitions, franchisee/distribution, commercial transactions and private equity with an emphasis on the automotive and cannabis industries.

APPENDIX : KEY MANAGEMENT


APPENDIX : KEY MANAGEMENT – BOARD AND ADVISEMENT

Nitin Kaushal, CPA, CAPresident, Anik Capital Corp.Mr. Kaushal has over 30 years of finance and investment expertise including having held a number of senior roles within Canadian investment banks, private equity and the venture capital industry.

Chris IrwinDirector, Partner at Irwin Lowy LLP.Mr. Irwin advises a number of public companies on a variety of matters including continuous disclosure and regulatory matters, reverse takeover transactions, initial public offerings and take over bids.

Chris Buysen, MPAcc CPA, CADirector, CFOMr. Buysen has over 15 years of diverse financial experience working as a senior financial executive with many public and private organizations in a wide range industries.

Tyler Robson, B.Sc.Director, CEO and Co-founderMr. Robson has over a decade of cannabis R&D, plant innovation and life sciences experience. He previously held the position of COO of Valens Agritech Ltd. “Top 100 Leaders in Health Care” by IFAH.

Ashley McGrathDirector, President & Owner of Glencoe Developments Inc.Mr. McGrath has been involved in real estate development for 14 years, overseeing all aspects of the development business and oversees the management of multiple development companies in the commercial, residential and agricultural space.

Deepak AnandDirector, Co-Founder and CEO of Materia VenturesMr. Anand is known as global leader in the cannabis sector for his regulatory, political and industry knowledge. Prior to starting Materia, he was the VP of Business Development & Regulatory Affairs at Cannabis Compliance Inc.

Phil DonneAdvisor, Past President/CEO of Campbell Company of Canada,Past CEO of Kellogg CanadaMr. Donne brings over 30 years of international brand management, re-structures and bold brand and communication initiatives including the launch of Vector cereal (the largest new cereal product in 20 years).

Brett ChannerAdvisor, CEO of Mass Minority, Past CEO of Saatchi + SaatchiMr. Channer has over 25 years of marketing industry experience. He was responsible for leading Saatchi Canada to “Most Improved Agency in Canada,” as well as one of the Top 10 creative agencies in Canada and becoming one of the top performing agencies for growth in the Saatchi Network.


APPENDIX : ANALYST OUTLOOK

Broker Date Rating Target ($C)

AltaCorp Capital Inc. Apr 15, 2020 Outperform $8.00

Canaccord Genuity May 15, 2020 Speculative buy $7.00

Desjardins Securities Inc. Apr 15, 2020 Buy $6.50

Eight Capital Apr 16, 2020 Buy $7.50

Haywood Securities Apr 16, 2020 Buy $6.75

Mackie Research Capital Corp. Feb 25, 2020 Buy $8.00

M Partners Inc. May 15, 2020 Buy $8.50


CONTACT USTORONTO

KELOWNA

409 King St WToronto, ON

230 Carion RdKelowna, BC

EMAIL

PHONE

[email protected]

1 647.956.8254

Documents

PowerPoint Presentation · This presentation (the “Presentation”) of Valens GroWorks Corp. (the “Company” or “The Valens Company” or “Valens”) is an overview only